How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial

BACKGROUND: Empagliflozin has been shown to reduce cardiovascular mortality, but the underlying pathogenetic mechanisms are poorly understood. It was previously demonstrated that empagliflozin improved arterial stiffness. METHODS: Our analysis comprising 58 patients with type 2 diabetes mellitus ide...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cardiovasc Diabetol
Autors principals: Bosch, Agnes, Ott, Christian, Jung, Susanne, Striepe, Kristina, Karg, Marina V., Kannenkeril, Dennis, Dienemann, Thomas, Schmieder, Roland E.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2019
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6440009/
https://ncbi.nlm.nih.gov/pubmed/30922297
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-019-0839-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars